![Quantification of Atherosclerotic Plaque Activity and Vascular Inflammation using [18-F] Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography FDG-PET/CT](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F3777.jpg&w=3840&q=50)
BRAF Inhibitor-Induced Panniculitis: Appearance on 18F-FDG PET/CT
Stephen M Broski1, Erin K Moran, Katrina N Glazebrook
1From the Department of Radiology, Mayo Clinic, Rochester, MN.
Clinical Nuclear Medicine
|October 9, 2015
Abstract:
BRAF inhibitors vemurafenib and dabrafenib have become the standard of care for treatment of stage IV metastatic melanoma harboring a BRAF mutation. Panniculitis is a rare but known adverse side effect of these agents and presents with tender erythematous nodules. These nodules may demonstrate uptake on F-FDG PET/CT, which may mimic metastatic disease in patients undergoing treatment. We present a case of BRAF inhibitor-induced panniculitis in a patient with stage IV metastatic melanoma and discuss the imaging findings on F-FDG PET/CT.
![PET/CT With [68Ga]-NOTA-FAP-2286 for Imaging of Tendon Injuries in Rat Achilles Tendon Injury Models](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F67717.jpg&w=3840&q=50)
